Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages.
A new British Journal of Surgery study indicates that a certain cocktail of chemotherapy drugs may be a safe and effective treatment option for patients with a metastatic form of the disease.
The study, which was an early-phase 46-patient trial intended to provide preliminary results regarding safety and efficacy, tested a strategy involving injections of paclitaxel into the abdomen and injections of gemcitabine and nab-paclitaxel (a combination of paclitaxel and a protein called albumin) into the blood.
The treatment had acceptable toxicities, and patients had a median survival time of 14.5 months, with a 1-year survival rate of 60.9%.
"Now, a phase 3 study to compare survival outcomes between this therapy and standard chemotherapy has been launched," said senior author Sohei Satoi, MD, of Kansai Medical University, in Japan.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.